Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
AZD6234 Medication Report
Name: AZD6234 Name (English): AZD6234
Drug Type: Synthetic peptide Target: Amylin receptor (AMYR) Action: Agonist Mechanism of Action: AZD6234 is a long-acting amylin receptor agonist. It mimics the effects of amylin, a hormone produced by the pancreas that helps to regulate blood glucose levels and appetite. AZD6234 delays gastric emptying, suppresses appetite, and promotes the release of glucagon from the pancreas.
Therapeutic Areas: Endocrinology and Metabolic Disease Active Indication: Obesity, Type 2 Diabetes Mellitus
Clinical Trials: AZD6234 is currently under investigation in several Phase II clinical trials, both as a monotherapy and in combination with other investigational drugs like AZD9550 (a GLP-1/glucagon agonist). These trials are evaluating its efficacy, safety, and tolerability in adults with overweight or obesity, including those with type 2 diabetes.
- ASCEND (D8460C00004): A Phase IIb study evaluating the co-administration of AZD9550 and AZD6234 in participants living with obesity or overweight with co-morbidity.
- APRICUS (D8750C00004): A Phase IIb study evaluating AZD6234 compared to placebo in participants living with obesity or overweight with at least one weight-related comorbidity.
- D8750C00002: A Phase I study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeated doses of AZD6234 in participants with overweight or obesity.
- Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist: A Phase II study in this specific population.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/12 | Phase 2 | Recruiting | |||
2025/06/10 | Phase 1 | Recruiting | |||
2025/03/06 | Phase 2 | Recruiting | |||
2025/02/28 | Phase 2 | Recruiting | |||
2025/02/25 | Phase 1 | Recruiting | |||
2024/09/19 | Phase 2 | Active, not recruiting | |||
2023/11/15 | Phase 1 | Recruiting | |||
2022/08/22 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.